
Roche

Roche

2018 results

London, 31 January 2019

This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

1 pricing and product initiatives of competitors;
2 legislative and regulatory developments and economic conditions;
3 delay or inability in obtaining regulatory approvals or bringing products to market;
4 fluctuations in currency exchange rates and general financial market conditions;
5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products;
6 increased government pricing pressures;
7 interruptions in production;
8 loss of or inability to obtain adequate protection for intellectual property rights;
9 litigation;
10 loss of key executives or other employees; and
11 adverse publicity and news coverage.

Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche.

For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com

Group

Severin Schwan
Chief Executive Officer

2018 performance

Outlook

2018: Targets fully achieved

Targets for 2018		2018	
Group sales growth[1]	Mid-single digit (raised at HY)	**+7%**	✓
Core EPS growth[1]	Broadly in line with sales growth, excl. US tax reform benefit Mid teens incl. US tax reform (raised at HY)	**+8%** **+19%**	✓
Dividend outlook	Further increase dividend in Swiss francs[2]	**CHF 8.70**	✓

[1] At constant exchange rates (CER); [2] 2018 dividend as proposed by the Board of Directors

2018: Strong sales growth in both divisions

	2018 CHFbn	2017 CHFbn	Change in % CHF	Change in % CER
Pharmaceuticals Division	**44.0**	41.2	**7**	**7**
Diagnostics Division	**12.9**	12.1	**7**	**7**
Roche Group	**56.8**	53.3	**7**	**7**

CER=Constant Exchange Rates

2018: Sales growth for the seventh consecutive year



All growth rates at Constant Exchange Rates (CER)

New products with strong momentum offsetting biosimilars impact





All absolute values are presented in CHFm reported; [1] Erivedge, Perjeta, Kadcyla, Gazyva, Esbriet, Cotellic, Alecensa, Tecentriq, Ocrevus, Hemlibra, and Xofluza; [2] MabThera and Herceptin in Europe and Japan

2018: Strong Core results, significant operating free cash flow

Core operating profit

% of sales



CHFbn



Core EPS

CHF



Operating free cash flow



CHFbn



CER=Constant Exchange Rates; [1]+8% at CER excl. US tax reform

Roche significantly advancing patient care

BTD's and BDD's reflecting the quality of our research

25 *Breakthrough Therapy Designations (BTD)*

Year	Molecule	Indication
2019	**Kadcyla**	Adjuvant HER2+ BC
2018	**satralizumab**	NMOSD
	Xolair	Food allergies
	Tecentriq + Avastin	HCC
	Hemlibra	Hemophilia A non-inhibitors
	entrectinib	NTRK+ solid tumors
	balovaptan	Autism spectrum disorders
2017	**polatuzumab vedotin + BR**	R/R DLBCL
	Venclexta + LDAC	1L unfit AML
	Zelboraf	BRAF-mutated ECD
	Rituxan	Pemphigus vulgaris
2016	**Actemra**	Giant cell arteritis
	Alecensa	1L ALK+ NSCLC
	Ocrevus	PPMS
	Venclexta + HMA	1L unfit AML
	Venclexta + Rituxan	R/R CLL
2015	**Actemra**	Systemic sclerosis
	Tecentriq	NSCLC
	Venclexta	R/R CLL 17p del
	Hemlibra	Hemophilia A inhibitors
2014	**Esbriet**	IPF
	Lucentis	Diabetic retinopathy
	Tecentriq	Bladder
2013	**Alecensa**	2L ALK+ NSCLC
	Gazyva	1L CLL

7 *Breakthrough Device Designations (BDD)*

Year	Device	Intended use
2018	**Elecsys β-Amyloid + p-Tau Cerebro Spinal Fluid assays**	AD: PET concordance AD: Progression
	sFlt + PLGF	Preeclampsia: rule-out within 1w
	FACT CDx (liquid biopsy assay)	70 oncogenes + MSI + bTMB
	cobas EBV	EBV in transplant patients
	cobas BKV	BKV in transplant patients
	CoaguChek Direct-X	Patients on Factor Xa

2018: Record number of NMEs at pivotal stage



NME=new molecular entities; risdiplam (SMN2 splicer); FDC=Fixed dose combination; SC=Subcutaneous; PDS=Port delivery system; For details on the indications and line extensions please consult the pipeline appendix

Replace and extend the business: Excellent progress in 2018

Replace/extend existing businesses

MabThera/Rituxan	Gazyva, Venclexta, polatuzumab vedotin, mosunetuzumab, aCD20/CD3 TCB
Herceptin	Perjeta, Kadcyla, Herceptin + Perjeta SC
Avastin	Tecentriq, Alecensa, entrectinib
Lucentis	faricimab Port delivery system (PDS)
Tamiflu	Xofluza

Entering new franchises

MS:
Ocrevus
satralizumab

Hemophilia A:
Hemlibra

CNS:
SMA, Autism, Huntington's, Alzheimer's, NMOSD

Achievements 2018
Approvals and major read-outs

Entering new franchises

Ocrevus:	EU approval in RMS/PPMS
satralizumab:	2 positive Ph III in NMOSD
Hemlibra:	US/EU/Japan launch in Hemophilia A
Venclexta:	US approval in R/R CLL & 1L AML
risdiplam:	Positive preliminary Ph II in SMA
balovaptan:	Start of Ph III in adults with autism

Replace/extend existing businesses

Gazyva+Ven:	Positive Ph III in 1L CLL
Kadcyla:	Positive Ph III in adjuvant HER2+ BC
Tecentriq:	US approval in 1L non-sq NSCLC; US/EU filing in 1L SCLC & TNBC
entrectinib:	US/EU filing ROS1+ NSCLC & NTRK+ tumors
faricimab:	Positive Ph II in nAMD and DME
PDS:	Positive Ph II in nAMD
Xofluza:	US approval in Influenza A and B

SMA=spinal muscular atrophy; NMOSD=neuromyelitis optica spectrum disorder; RMS=relapsing MS; PPMS=primary progressive MS; R/R CLL=relapsed/refractory chronic lymphocytic leukemia; AML=acute myeloid leukemia; BC=breast cancer; NSCLC=non-small cell lung cancer; SCLC=small cell lung cancer; TNBC=triple-negative BC; nAMD=neovascular age-related macular degeneration; DME=diabetic macular edema

2018: 32nd consecutive annual dividend increase



2018 dividend as proposed by the Board of Directors; Note: For 1995, a special dividend was paid out to mark F. Hoffmann-La Roche's 100th anniversary in 1996

2018 performance

Outlook

2019: Roche significantly advancing patient care

Another strong year expected

3	**NME launches**	• Xofluza (baloxavir marboxil) • entrectinib in ROS1+ and NTRK+ tumors* • polatuzumab vedotin in R/R DLBCL*
7	**Major line extension launches**	• Hemlibra (non-inhibitor) in EU • Kadcyla in adj HER2+ BC • Venclexta in 1L AML and 1L CLL • Tecentriq in 1L TNBC, 1L SCLC, 1L NSCLC
2	**Major NME filings**	• satralizumab in NMOSD • risdiplam in SMA
1	**Diagnostics platform**	• Further roll-out of cobas pro integrated solutions

*filed end of 2018; NME=new molecular entities; R/R CLL=relapsed/refractory diffuse large B-cell lymphoma; AML=acute myeloid leukemia; CLL= chronic lymphocytic leukemia; TNBC=triple-negative BC; SCLC=small cell lung cancer; NSCLC=non-small cell lung cancer; NMOSD=neuromyelitis optica spectrum disorder; SMA=spinal muscular atrophy

2019 outlook

Group sales growth[1]	• Low-to mid-single digit
Core EPS growth[1]	• Broadly in line with sales
Dividend outlook	• Further increase dividend in Swiss francs

[1] At Constant Exchange Rates (CER)

Pharmaceuticals Division

Bill Anderson
CEO Roche Pharmaceuticals

2018: Pharma Division sales

Strong growth in US due to new products

	2018 CHFm	2017 CHFm	Change in % CHF	Change in % CER
Pharmaceuticals Division	**43,967**	**41,220**	**7**	**7**
United States	23,233	20,496	13	14
Europe	8,693	9,051	-4	-7
Japan	3,701	3,713	0	-1
International	8,340	7,960	5	10

CER=Constant Exchange Rates

2018: Pharma Division

Core operating profit outgrowing sales

	2018 CHFm	2018 % sales
Sales	**43,967**	**100.0**
Royalties & other op. inc.	2,553	5.8
Cost of sales	-9,504	-21.6
M & D	-6,939	-15.8
R & D	-9,586	-21.8
G & A	-1,549	-3.5
Core operating profit	**18,942**	**43.1**

2018 vs. 2017
CER growth



CER=Constant Exchange Rates; COGS=costs of goods sold; PC=period costs

2018: Portfolio rejuvenation in full swing

Growth exclusively driven by new products



Absolute values and growth rates at Constant Exchange Rates (CER)

2018: Oncology grows +2% with new products offsetting biosimilars



Oncology Q4 update

HER2

- Perjeta: Accelerated growth driven by eBC (APHINITY)
- Herceptin: Impact from biosimilars in EU as expected

Hematology

- Venclexta*: Accelerated momentum due to strong 1L AML launch
- Gazyva: Growth remains driven by 1L FL
- MabThera/Rituxan: Biosimilar erosion rate stabilizing in EU

Tecentriq

- Sales momentum in all geographies, upcoming new launches

Alecensa

- Strong 1L launch momentum in all key markets

* **Venclexta sales of USDm 344 (+177% YoY)** are booked by partner AbbVie and therefore not included; 2018 Oncology sales: CHF 26.2bn; CER growth +2%; CER=Constant Exchange Rates; eBC=early breast cancer; AML=acute myeloid leukemia; FL=follicular lymphoma

HER2 franchise

Kadcyla in adjuvant HER2+ eBC for patients with residual disease

Kadcyla: Ph III (KATHERINE) results

Invasive disease free survival

FDA BTD



Standard of care (SOC) evolution



- New SOC in patients with residual invasive disease after neoadjuvant chemo and HER2 targeted therapy
- Increased use of neoadjuvant therapy in HER2-positive eBC expected
- BTD granted; US/EU filing and US approval expected in 2019

Geyer E.C. et al., SABCS 2018; eBC=eary breast cancer; HR=hazard ratio; OS=overall survival; H+P=Herceptin+Perjeta; FDC=fixed dose combination; Kadcyla=trastuzumab emtansine (T-DM1)

Emerging triple negative breast cancer (TNBC) franchise

Tecentriq + chemo new SOC in 1L PDL1+ patients

Tecentriq+nab-pac: Ph III (IMpassion130)



TNBC program covering all lines of treatment*



- PFS in ITT (HR=0.80) and PD-L1+ patients (HR=0.62); Interim OS with clinically meaningful improvement in PD-L1+ patients (HR=0.62) with mOS improvement from 15.5m to 25.0m
- US/EU filing completed (PDUFA March 12)

Schmid P, et al. ESMO 2018 (Data cutoff: 17 April 2018); TNBC=triple negative breast cancer; nab-pac=nab-paclitaxel (Abraxane); ITT=intent to treat; HR=hazard ratio; OS=overall survival;
*Outcome studies are event-driven: timelines may change

Hematology franchise

Broadest portfolio with 12 assets in combination trials



*Venclexta in collaboration with AbbVie; polatuzumab vedotin in collaboration with Seattle Genetics; Cotellic in collaboration with Exelixis; NHL=non-hodgkin`s lymphoma; FL = follicular lymphoma; CLL=chronic lymphoid leukemia; MM=multiple myeloma; MDS=myelodysplastic syndrom; AML=acute myeloid leukemia; MCL=mantle cell lymphoma; DLBCL=diffuse large B cell lymphoma

Hematology franchise

Redefining the SOC and expanding into new indications

60th ASH® Annual Meeting & Exposition
San Diego, CA • December 1-4, 2018

Continuing to redefine the SOC in B-cell malignancies



Expanding into new indications with transformative therapies



Datamonitor: incidence rates includes the 7 major markets (US, Japan, France, Germany, Italy, Spain, UK); SOC=standard of care; CLL=Chronic lymphoid leukemia; DLBCL=Diffuse large B-cell lymphoma; iNHL=Indolent Non-Hodgkin's lymphoma; AML=Acute myeloid leukemia; MM=Multiple myeloma; MDS=Myelodysplastic syndrome; ALL=Acute lymphoblastic leukemia; Venclexta in collaboration with AbbVie; polatuzumab vedotin in collaboration with Seattle Genetics

Hematology franchise

Venclexta + HMA/LDAC new SOC in 1L unfit AML

Roche

60th ASH® Annual Meeting & Exposition
San Diego, CA • December 1-4, 2018

FDA BTD

AML incidence rate[1]



- Incidence rate: US 19.2k; EU5 15.1k
- ~50% of 1L AML patients unfit for intense chemotherapy

PhIb/II update in 1L unfit AML

CR rates doubled compared to historical SOC

	Ven (400mg) + azacitadine	Ven (400mg) + decitabine	azacitadine (historical data)[2]
CR	44%	55%	~20%
CR+CRi	71%	74%	~28%
MRD-negative	48%	39%	N/A
mOS	16.9m	16.2m	10.4m

- **1L AML**: Accelerated FDA approval in 1L unfit AML achieved; Two confirmatory Ph III trials (Viale-A, Viale-C) in 1L AML ongoing
- **R/R AML**: Promising early activity of Venclexta+idasanutlin presented; Ph III (MIRROS) results of idasanutlin+chemo expected in 2019

Pollyea, *et al.*, ASH 2018; 2 Dombert H., et al., International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. *Blood.* 2016;126 (3): 291-299; [1] Datamonitor: incidence rates includes the 7 major markets (US, Japan, France, Germany, Italy, Spain, UK); SOC=standard of care; AML=acute myeloid leukemia; HMA=hypomethylating agent; LDAC=low dose aracytarabine; MRD=minimal residual disease: CR=complete response; mOS=median overall survival; Venclexta in collaboration with AbbVie

Hematology franchise

TCBs with strong efficacy and tolerable safety in NHL

60th ASH® Annual Meeting & Exposition
San Diego, CA • December 1-4, 2018

Mosunetuzumab: Ph I/Ib dose escalation



ORR 16/47 (34.0%)
CR 9/47 (19.1%)

ORR 18/26 (69.2%)
CR 10/26 (38.5%)

aCD20/CD3 TCB: Ph Ib dose escalation



aNHL/DLBCL 10mg cohort*
ORR 9/15 (60%)
CR 5/15 (33%)

- Durable CRs as a single agent in 2L+ iNHL/aNHL
- CRs in patients refractory to R-CHOP and CAR-T
- Combination trials with Tecentriq, polatuzumab vedotin and CHOP ongoing
- Dose escalation ongoing

Budde L., et al, ASH 2018; Hutchings, M., et al, ASH 2018; CAR T cells=chimeric antigen receptor; CR=complete response; SPD=sum of the product diameters; R/R=relapsed/refractory; DLBCL=diffuse large B-cell lymphoma; FL=Follicular Lymphoma; AE=adverse event; NHL=non-Hodgkin's lymphoma; TCB=T=cell bispecific; *aNHL includes FL Grade 3B, DLBCL, trFL, PMBCL, MCL, trMZL, RS and DLBCL/MCL

Immunology franchise

Immunology sales hit CHF 8bn driven by well differentiated products



Immunology Q4 update

Esbriet

- Strong growth in mild to moderate patient segments

Actemra

- Ongoing launches in giant cell arteritis (GCA) and of pre-filled syringe in pJIA and sJIA
- US: Autoinjector approval received

Xolair

- Growth driven by CIU, pediatric asthma and allergic asthma
- Pre-filled syringe launched; Self-administration filing ongoing

CER=Constant Exchange Rates; pJIA= polyarticular juvenile idiopathic arthritis; sJIA=systemic juvenile idiopathic arthritis; RA=rheumatoid artheritis; CIU=chronic idiopathic urticaria

Neuroscience franchise

Ocrevus with 15% total US market share after 20 months



Ocrevus Q4 update

- Strong launches in EU and International
- US driven by earlier lines, new and returning patients
- 5-Year efficacy and safety data presented at ECTRIMS
- Continue to generate new data in progressive MS (PMS) including new Phase III study using upper limb function and digital outcomes as measures of progression

Outlook 2019

- Moving into earlier lines displacing orals
- Continued launches in EU and International

CER=Constant Exchange Rates

Neuroscience franchise

Risdiplam in spinal muscular atrophy (SMA) types 1/2/3

SMN2 splicing modifier



- Oral and systemically available SMN2 splicing modifier
- Durably increases SMN protein both in the CNS and in the periphery
- To date well tolerated at all doses assessed

Phase II/III (FIREFISH) Part 1 data in Type 1 SMA:

Median change from baseline in CHOP-INTEND



HINE-2 motor milestones

	Baseline (n=21)	8 months (n=14)
Upright head control	0%	43%
Kicking	5%	50%
Rolling	0%	29%
Stable sitting	0%	21%

- 20/21 babies (95%) were alive and without need of permanent ventilation at 10.5m, compared with 50% of babies at the same age in natural history studies
- No patients have lost the ability to swallow or reached permanent ventilation
- Among babies with 8m treatment: median change in CHOP-INTEND was 16 points and 21% achieved unassisted stable sitting
- Presymptomatic Ph III (RAINBOWFISH) in 0-6 week old babies starting in Q1 2019
- NME filing targeted in H2 2019

Baranello G. et al., WMS 2018; WMS=world muscle society; SMA=spinal muscular atrophy; CHOP-INTEND=Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (16-item 64-point motor assessment designed specifically to evaluate the motor skills of infants with SMA); HINE-2=Hammersmith Infant Neurological Examination Module 2; Risdiplam in collaboration with PTC Therapeutics and the SMA Foundation

Hemophilia A franchise

Hemlibra with strong initial uptake in non-inhibitors



Hemlibra Q4 update

- US: Strong uptake in non-inhibitors and further market share gains in inhibitors
- Germany, France, UK: Inhibitor market share gains
- Strong preference data for Hemlibra in patients previously receiving episodic (92% preference) or prophylactic factor treatment (99% preference)

Outlook 2019

- US: Uptake in non-inhibitors and inhibitors
- EU: Launch in non-inhibitors and Q2W/Q4W dosing

CER=Constant Exchange Rates; Q2w=every 2 weeks dosing; Q4w=every 4 weeks dosing

New products close to annualized sales of CHF 11bn*

Late stage pipeline keeps delivering with 4 NMEs approaching launch





* Venclexta sales are booked by partner AbbVie and therefore not included.

2018: Key late-stage news flow*

	Compound	Indication	Milestone	
Regulatory	**Ocrevus**	RMS / PPMS	EU approval	✓
	Perjeta + Herceptin	Adjuvant HER2+ eBC	EU approval	✓
	Tecentriq + cb/pac +/- Avastin	1L non-sq NSCLC	US/EU filing	✓
	Tecentriq + Avastin	1L RCC	US/EU filing	
	Hemlibra	Hemophilia A inhibitors	EU approval	✓
	Hemlibra	Hemophilia A non-inhibitors	US/EU filing; US approval	✓
	Hemlibra	Every 4 weeks dosing inhibitors/non-inhibitors	US/EU filing	✓
	Xofluza	Acute uncomplicated influenza	US filing	✓
	Venclexta + Rituxan	R/R CLL	US/EU approval	✓
Phase III readouts	**Tecentriq + chemo**	1L non-sq NSCLC	Ph III IMpower130	✓
	Tecentriq + chemo	1L sq NSCLC	Ph III IMpower131	✓
	Tecentriq + chemo	1L non-sq NSCLC	Ph III IMpower132	✓
	Tecentriq + chemo	1L extensive-stage SCLC	Ph III IMpower133	✓
	Tecentriq + nab-pac	1L TNBC	Ph III IMpassion130	✓
	Tecentriq + Cotellic	2/3L CRC	Ph III IMblaze370 / COTEZO	✗
	Actemra	Systemic sclerosis	Ph III focuSSced	✗

Additional 2018 news flow:

- **Actemra**: EU approval of CAR T-cell induced cytokine release syndrome
- **MabThera/Rituxan**: US approval of pemphigus vulgaris
- **Avastin + carboplatin and paclitaxel**: US approval of 1L advanced OC following surgery
- **Gazyva + ibrutinib**: Positive Ph III results in 1L CLL (iLLUMINATE)
- **Venclexta + HMA/LDAC**: Early US filing/approval of PhI/II results in 1L unfit AML
- **polatuzumab vedotin**: Early US filing of Ph II results in R/R DLBCL
- **Hemlibra:** Positive Ph III results in hemophilia A non-inhibitors (HAVEN3/4)
- **entrectinib:** Positive pivotal Ph II results in ROS1+ NSCLC (ALKA, STARTRK1/2)
- **entrectinib:** Positive pivotal Ph II results in NTRK+ tumors (ALKA, STARTRK1/2)
- **risdiplam:** Positive preliminary Ph II/III results in type 1 SMA (FIREFISH)
- **Xofluza:** US approval and positive Ph III results in high risk influeza (CAPSTONE-2)
- **Kadcyla:** Positive Ph III results in eBC (KATHERINE)
- **MabThera/Rituxan:** US approval of rare forms of vasculitis (GPA/MPA)
- **satralizumab:** Positive Ph III results in NMOSD

* Outcome studies are event-driven: timelines may change

2019: Key late-stage news flow*

	Compound	Indication	Milestone	
Regulatory	**entrectinib**	ROS1+ NSCLC	US filing/approval; EU filing	
	entrectinib	1L NTRK+ pan tumor	US filing/approval; EU filing	
	polatuzumab vedotin	R/R DLBCL	US/EU approval	
	Tecentriq + chemo	1L PDL1+ TNBC	US/EU approval	
	Tecentriq + chemo	1L SCLC	US/EU approval	
	Xofluza	High risk influenza	US approval	
	Kadcyla	Adjuvant HER2+ BC	US filing/approval; EU filing	
	Hemlibra	Non-inhibitors	EU approval	
	Tecentriq + Avastin + chemo	1L NSCLC	EU approval	
	Venclexta + chemo	1L unfit AML	EU filing	
	Venclexta + Gazyva	1L unfit CLL	US/EU filing	
	satralizumab	Neuromyelitis optica spectrum disorders	US/EU filing	
	risdiplam	SMA type 1/2/3	US filing	
Phase III / pivotal readouts	**Tecentriq + Zelboraf +/- Cotellic**	1L BRAF+ Mel, BRAFwt Melanoma	Ph III IMspire150 (TRILOGY) / IMspire170	
	Tecentriq	Adjuvant high-risk MIBC	Ph III IMvigor010	
	Tecentriq + chemo	Neoadjuvant TNBC	Ph III IMpassion031	
	Tecentriq + Avastin	1L HCC	Ph Ib/IMbrave150	
	Venclexta + Gazyva	1L CLL	Ph III CLL14	✓
	idasanutlin + chemo	R/R AML	Ph III MIRROS	
	Venclexta + chemo	R/R MM	Ph III BELLINI	
	risdiplam	SMA type 2/3	Ph II SUNFISH	

* Outcome studies are event-driven: timelines may change

Diagnostics Division

Michael Heuer
CEO Roche Diagnostics

2018: Diagnostics Division sales

Strong sales growth with all business units contributing

	2018 CHFm	2017 CHFm	Change in % CHF	Change in % CER
Diagnostics Division	**12,879**	**12,079**	**7**	**7**
Centralised and Point of Care Solutions	7,768	7,179	8	8
Molecular Diagnostics	2,019	1,920	5	5
Diabetes Care	1,980	1,965	1	2
Tissue Diagnostics	1,112	1,015	10	10

CER=Constant Exchange Rates; Underlying growth of Molecular Diagnostics excluding sequencing business: +6%

2018: Diagnostics Division regional sales

Growth driven by Asia Pacific and North America



+14% growth in E7 countries[2]

[1] Europe, Middle East and Africa; [2] Brazil, China, India, Mexico, Russia, South Korea, Turkey; All growth rates at Constant Exchange Rates

2018: Diagnostics Division highlights

Strong growth driven by Centralised and Point of Care Solutions



- Immunodiagnostics (+11%); Clinical chemistry (+7%)
- POC MDx[2] (+162%); Blood screening (+9%); Virology (+4%); HPV (+8%)
- Blood glucose monitoring (+2%); insulin delivery systems (-6%)
- Advanced staining (+10%); Companion diagnostics (+9%); Primary staining (+13%)

[1] Underlying growth of Molecular Diagnostics excluding sequencing business: +6%; CER=Constant Exchange Rates; EMEA=Europe, Middle East and Africa; [2] Point of Care Molecular Diagnostics

2018: Diagnostics Division

Core operating profit outgrowing sales

	2018 CHFm	2018 % sales
Sales	**12,879**	**100.0**
Royalties & other op. inc.	82	0.6
Cost of sales	-5,960	-46.3
M & D	-2,966	-23.0
R & D	-1,461	-11.3
G & A	-528	-4.1
Core operating profit	**2,046**	**15.9**



CER=Constant Exchange Rates

Integrated Core Lab

Expansion with additional solutions and entering new disciplines



*cobas pure and cobas Mass Spec have not been launched, yet.

Launch of cobas pro integrated solutions
Next generation medium throughput SWA solution

cobas pro integrated solutions

cobas connection modules (CCM)
cobas p 512, cobas p 612

cobas p 701 post-analytical unit

- Targeting medium to high throughput labs
- New clinical chemistry module cobas c 503 in combination with immunochemistry module cobas e 801
- Substantially higher capacity compared to cobas 6000 on the same footprint
- Enhanced automated procedures such as maintenance, calibration and on-the fly reagent loading

SWA=serum work area

Growth hormone portfolio completed with Elecsys IGFBP-3 test

Providing diagnosis and treatment decisions

Reagent cartridge for Insulin-like growth factor binding protein 3 (IGFBP-3)

- Complete menu by providing tests for all three main proteins related to growth hormone disorders:
  - Insulin-like growth factor 1 (IGF-1, Somatomedin C)
  - Insulin-like growth factor binding protein 3 (IGFBP-3)
  - Human Growth Hormone (hGH, Somatotropin)
- Available on all cobas e modules

Launch of cobas connection modules (CCM) for cobas c 513

Enabling high throughput diagnosis and monitoring for diabetes

Multidisciplinary connectivity

- Clinical Chemistry
- Immunochemistry
- Hematology
- Coagulation
- Molecular Diagnostics — Unique in the market
- Specialized Infectious Diseases
- Urinalysis — Unique in the market
- Allergy
- Post-analytics
- HbA1c testing — NEW

Number of CCM installations: >600*



* Life-time installations, June 2018

Global Access Program

Providing access to HIV testing in Africa and beyond

Expanding access



Growing customers

- Tender win for five cobas 8800 and one cobas 6800, Nigeria
- Installation of cobas 8800 at KEMRI/CDC* laboratory, Kenya

Innovation

- Q1 2018 launch of the cobas Plasma Separation Card
- Q4 2018 launch of dried blood spot sample type for early infant diagnosis

*KEMRI: Kenya Medical Research Institute, CDC: Centers for Disease Control

Completing the digital pathology workflow

uPath enterprise software enables automated data analysis and information sharing

- Enhances the efficiency of pathology laboratory workflow with connectivity and automation
- Case management and collaboration between pathologists including remote consultation
- Automated image analysis
- Patient case evaluation and report generation

Key launches 2018

	Area	Product	Market
Instruments/ Devices	**Central Laboratory**	cobas pro integrated solution – Serum Work Area solution for medium throughput to lower high throughout labs	CE ✓
	Specialty Testing	cobas m 511 – World's first fully digital morphology analyzer and cell counter	US
	Workflow	CCM connectivity to cobas c513 – Connection of cobas c 513 to CCM Automation System for high volume HbA1c testing	WW ✓
	Tissue Dx	BenchMark ULTRA Plus – New and differentiated Advanced Staining System	CE
	Digital Pathology	VENTANA DP200 – Reliable low-volume scanner with superior image quality	CE ✓
	Diabetes Care	Accu-Chek Solo micropump – Small and tubeless insulin delivery device operated through a remote control which includes a blood glucose meter	CE ✓
Tests/ Assays	**Endocrinology**	IGFBP3 – Completion of the existing growth hormone menu of hGH and IGF-1	CE ✓
	Infectious Diseases	Zika IgG – Highly specific immunoassay for the in vitro qualitative detection of IgG antibodies to Zika virus in human serum and plasma	CE ✓
	Microbiology	cobas CT/NG – Highest throughput CT/NG test on the market with workflow efficiency benefits	US ✓
		cobas 6800/8800 MTB/MAI – High volume solution for MTB/MAI testing; efficient approach to disease management (mixed testing) for infectious disease	CE ✓
	Virology	Plasma Separation Card – Card-like sample collection device; separates plasma from whole blood; for use with CAP/CTM HIV-1 & cobas HIV-1 (6800/8800)	CE ✓
	Sequencing	AVENIO FFPET RUO oncology kits – 3 separate tissue based assay kits for solid tumors	WW ✓
Software	**Decision Support**	NAVIFY Tumor Board v 1.x – EMR integration	WW ✓

Key launches 2019

	Area	Product	Description	Market[1]
Instruments/ Devices	**Workflow**	cobas prime	Pre-analytical platform to support cobas 6800/8800	CE/US
Tests/ Assays	**Coagulation**	Protein C Chrom	Quantitative determination of protein C in citrated plasma on cobas t 511 / t 711 analyzers	CE
	Microbiology	cobas TV/MG	High volume solution for TV/MG testing; dual-target test with ability to test with CT/NG from the same specimen during the same run	US
		cobas vivoDx MRSA	Live cell assay for prevention and control of MRSA infections	CE
	Tissue Dx	VENTANA HER2 Dual ISH	Fully automated, brightfield ISH assay to determine eligibility for HER2 targeted therapy	CE
Software	**Central Laboratory**	cobas Infinity Central Lab 3.0	One global laboratory middleware solution realizing a very high degree of integration in the laboratory	WW
	Tissue Dx	Algorithm - Breast Panel	Whole slide analysis image analysis algorithm (HER2, ER, PR, Ki-67)	CE
		Algorithm - PD-L1 Lung	Whole slide analysis image analysis algorithm (SP263)	CE
	Sequencing	NAVIFY Mutation Profiler	Software as a medical device for annotating, variant classification, clinical interpretation and reporting from comprehensive genomic profile testing	CE/US
		NAVIFY Therapy Matcher	Informing on treatment options based on local drug labels, medical guidelines and clinical trial outcomes	CE/US
	Decision Support	NAVIFY Tumor Board V2	Integrating a GEHC DICOM imaging viewer into the Tumor Board to support the radiologist	WW
		NAVIFY Oncology Workflow V1	Integration of patient's longitudinal history, diagnosis, and treatment planning by leveraging relevant guidelines	WW
	Diabetes Care	Accu-Chek Sugar View 2.0 (non-ISO)	For non-insulin dependent T2 PwDs, allowing for meter-free blood glucose monitoring using Accu-Chek Active test strips and a smartphone camera	CE

[1] CE: European Conformity, US: FDA approval, WW: Worldwide; GEHC DICOM: GE Healthcare Digital Imaging and Communications in Medicine; T2: Type II Diabetes; PwDs: People with Diabetes

Finance

Alan Hippe
Chief Financial Officer

2018 results

Focus on Cash

Outlook

2018: Highlights

Business

- Sales growth of +7%[1] despite biosimilars impact of CHF -1.3bn[1]
- Core operating profit up +9%[1] and Core EPS growth of +19%[1] (+8%[1] excluding US tax reform)
- Dividend in Swiss francs further increased

Cash flow

- Significant cash generation (Operating Free Cash Flow of CHF 18.7bn, +5%[1])
- Net debt lower by CHF 1.3bn vs. YE 2017 as Free Cash Flow of CHF 14.8bn more than offsets dividends paid (CHF -7.3bn) and cash outflow for M&A (CHF -5.7bn)

Net financial results

- Core net financial result improved by +19%[1] due to higher income from equity securities

IFRS

- Net income +24%[1] driven by the operating results and the US tax reform impacts

[1] At Constant Exchange Rates (CER)

2018: Group performance

Strong Core EPS growth (+19%, +8% excl. US tax reform)

	2018 CHFm	2017 CHFm	Change in % CHF	Change in % CER
Sales	**56,846**	**53,299**	**7**	**7**
Core operating profit	**20,505**	**19,012**	**8**	**9**
as % of sales	*36.1*	*35.7*		
Core net income	**15,981**	**13,404**	**19**	**20**
as % of sales	*28.1*	*25.1*		
Core EPS (CHF)	**18.14**	**15.34**	**18**	**19**
IFRS net income	**10,865**	**8,825**	**23**	**24**
Operating free cash flow	**18,741**	**17,827**	**5**	**5**
as % of sales	*33.0*	*33.4*		
Free cash flow	**14,811**	**13,420**	**10**	**11**
as % of sales	*26.1*	*25.2*		

+8% at CER excl. US tax reform

CER=Constant Exchange Rates

2018: Group operating performance

Core operating profit growth ahead of sales growth

	2018 CHFm	2018 abs. CER
Sales	**56,846**	**+3,809**
Royalties & other op. inc.	2,635	+197
Cost of sales	-15,464	-1,185
M & D	-9,905	-418
R & D	-11,047	-641
G & A	-2,560	-93
Core operating profit	**20,505**	**+1,669**
Core OP in % of sales	**36.1**	



CER=Constant Exchange Rates

2018: Core operating profit and margin further improved



[1] At Constant Exchange Rates (CER)

2018: Core net financial result



CER = Constant Exchange Rates (avg full year 2017); [1] incl. amortisation of debt discount and net gains on interest rate derivatives

Core net financial result: Continuous improvement



Effective int. rate	*3.7%*	*2.9%*	*2.8%*	*3.0%*

2018: Group Core tax rate

Figures in %



2018: Non-core items; IFRS result impacted by impairments of goodwill & intangible assets

Full Year	2017	2018	CHFm	CHF	CER
Core operating profit	**19,012**	**20,505**	**+1,493**	**+8%**	**+9%**
Global restructuring plans	-1,208	-907	+301		
Amortisation of intangible assets	-1,691	-1,294	+397		
Impairment of intangible assets[1]	-3,518	-3,336	+182		
Alliances & Business Combinations	+350	-35	-385		
Legal & Environmental[2]	+58	-164	-222		
Total non-core operating items	-6,009	-5,736	+273		
IFRS operating profit	**13,003**	**14,769**	**+1,766**	**+14%**	**+15%**
Total financial result & taxes	-4,178	-3,904	+274		
IFRS net income	**8,825**	**10,865**	**+2,040**	**+23%**	**+24%**

CER=Constant Exchange Rates; [1] incl. goodwill [2] incl. pension plan settlements

2018 results

Focus on Cash

Outlook

2018: Operating free cash flow and margin



[1] At Constant Exchange Rates (CER)

2018: Operating free cash flow

Higher than previous year (+5%) due to higher OP



CER = Constant Exchange Rates (avg full year 2017); OP=operating profit; NTWC=net trade working capital; NWC=net working capital; PP&E=property, plant & equipment; IA=intangible assets

Operating free cash flow: Continuous improvement



2018: Group net debt lower driven by strong cash generation (CHF 1.3bn vs. YE 2017)



CER = Constant Exchange Rates (avg full year 2017)

Balance sheet 31 December 2018

Equity ratio at 39% (31 December 2017: 38%)



CER = Constant Exchange Rates (avg full year 2017)

2018 results

Focus on Cash

Outlook

Low currency impact in 2018





In 2018 impact is (%p):

	Q1	HY	Sep YTD	FY
Sales	**-1**	**0**	**0**	**0**
Core operating profit		**0**		**-1**
Core EPS		**1**		**-1**

***2019** currency impact[1] expected (based on **31 Dec 2018** FX rates):*

- Around -1%p FX impact on Sales, Core OP & Core EPS

[1] On group growth rates

2018: Core EPS

Core EPS 2018 of CHF 18.30 is basis for Core EPS outlook 2019 at CER



CER=Constant Exchange Rates (avg full year 2018)

2019 outlook

Group sales growth[1]	• Low-to mid-single digit
Core EPS growth[1]	• Broadly in line with sales
Dividend outlook	• Further increase dividend in Swiss francs

[1] At Constant Exchange Rates (CER)

Pipeline summary

Changes to the development pipeline
FY 2018 update

New to phase I

3 NMEs:
RG6217 - HBV
RG6237 - neuromuscular disorders
RG7769 PD1-TIM3 biMAb - solid tumors
1 AI:
RG7601 Venclexta + gilteritinib – r/r AML

New to phase II

2 NMEs transitioned from Ph1
RG7906 - psychiatric disorders
RG6058 tiragolumab + Tecentriq - NSCLC
1 NME starting Ph2
RG6180 iNeST (personalized cancer vaccine) + pembrolizumab - malignant melanoma
1 NME following termination of Ph3
RG7412 crenezumab – familial Alzheimer's disease healthy individuals

1 AI:
RG7446 Tecentriq SC – NSCLC

New to phase III

1 NME transitioned from Ph2:
RG6042 HTT ASO - Huntington's
6 AIs:
RG7446 Tecentriq – Her2-pos. BC neoadj
RG7446 Tecentriq – high risk NMIBC
RG6152 Xofluza - influenza hosp. patients
RG6152 Xofluza – influenza pediatric patients
RG7601 Venclexta - r/r MM t(11:14)
RG7601 Venclexta + HMA/LDAC - 1L AML*

New to registration

2 NMEs + 1 AI transitioned from Ph2 following filing in EU and US:
RG7596 polatuzumab vedotin - r/r DLBCL
RG6268 entrectinib - NSCLC ROS1+
RG6268 entrectinib – NTRK1 pan-tumor
3 AIs transitioned from Ph3 following filing in EU and US:
RG7446 Tecentriq + nab-paclitaxel 1L non sq NSCLC
RG7446 Tecentriq + nab-paclitaxel 1LTNBC
RG7446 Tecentriq + chemo - 1L extensive stage SCLC

Removed from phase I

2 NMEs:
RG7813 CEA IL2vFP + Tecentriq – solid tumors
RG6080 nacubactam – bacterial infections
2 AIs:
RG7876 selicrelumab + Tecentriq – solid tumors
RG7446 T+ Gazyva / tazemetostat – r/r DLBCL & FL

Removed from phase II

1 NME:
PRO VAP 1 inhibitor - inflammatory diseases
1AI:
RG7601 Venclexta + Rituxan +/- bendamustine - r/r FL

Removed from phase III

1 NME:
RG7412 crenezumab – Alzheimer's disease

Removed from registration

2 AIs following US approval:
RG1569 Actemra autoinjector - RA
RG7601 Venclexta + HMA/LDAC -1L AML
1 AIs following EU approval:
RG7601 Venclexta + Rituxan - r/r CLL

Status as of January 31, 2019

*study ongoing and lead by Abbvie

Roche Group development pipeline

Phase I (40 NMEs + 21 AIs)

RG6026	CD20 TCB ± chemo ± T	heme tumors
RG6109	-	AML
RG6114	mPI3K alpha inh	HR+ BC
RG6123	-	solid tumors
RG6146	BET inh combos	solid & heme tumors
RG6148	-	HER2 expressing BC
RG6160	-	multiple myeloma
RG6171	SERD (3)	ER+ (HER2-) mBC
RG6180	iNeST*± T	solid tumors
RG6185	pan-RAF inh + Cotellic	solid tumors
RG6194	HER2/CD3 TDB	BC
RG7159	anti-CD20 combos	heme tumors
RG7421	Cotellic + Zelboraf + T	melanoma
	Cotellic + T	2L BRAF WT mM
	Cotellic + T	RCC, bladder, head & neck ca
RG7440	ipatasertib + Taxane + T	TNBC
RG7446	Tecentriq (T)	solid tumors
	Tecentriq (T)	NMIBC
	T-based Morpheus platform	solid tumors
	T + Avastin + Cotellic	2/3L CRC
	T ± Avastin ± chemo	HCC, GC, PaC
	T + Tarceva/Alecensa	NSCLC
	T + anti-CD20 combos	heme tumors
	T ± lenalidomide ± daratumumab	MM
	T + K/HP	HER2+ BC
	T + radium 223	mCRPC
	T + rucaparib	ovarian ca
RG7461	FAP IL2v FP combos	solid tumors
RG7601	Venclexta + idasanutlin	AML
	Venclexta ± azacitidine	r/r MDS
	Venclexta + gilteritinib	r/r AML
	Venclexta + Cotellic + T	MM
RG7769	PD1-TIM3 biMAb	solid tumors
RG7802	cibisatamab ± T	solid tumors
RG7827	FAP-4-1BBL FP	solid tumors
RG7828	mosunetuzumab ± T	heme tumors
RG7876	selicrelumab + Avastin	solid tumors
CHU	Raf/MEK dual inh	solid tumors
CHU	glypican-3/CD3 biMAb	solid tumors
CHU	codrituzumab	HCC
RG6107	C5 inh MAb	PNH
RG6151	-	asthma
RG6173	-	asthma
RG6174	-	inflammatory diseases
RG7835	-	autoimmune diseases
RG7880	IL-22Fc	inflammatory diseases
RG6004	HBV LNA	HBV
RG6217	-	HBV
RG7854	TLR7 agonist (3)	HBV
RG7861	anti-S. *aureus* TAC	infectious diseases
RG7907	HBV CpAM (2) (Capsid)	HBV
RG7992	FGFR1/KLB MAb	metabolic diseases
RG6000	-	ALS
RG6049	-	neurodegenerative disorder
RG6237	-	neuromuscular disorder
RG7816	GABA Aa5 PAM	autism
RG6147	-	geographic atrophy
RG7774	-	retinal disease
CHU	PTH1 recep. ago	hypoparathyroidism
CHU	-	hyperphosphatemia
CHU	-	endometriosis

Phase II (13 NMEs + 10 AIs)

RG6180	iNeST* + pembrolizumab	malignant melanoma
RG6058	tiragolumab ± T	NSCLC
RG7388	idasanutlin	polycythemia vera
RG7421	Cotellic + Tecentriq ± taxane	TNBC
RG7440	ipatasertib	TNBC neoadj
RG7446	Tecentriq SC	NSCLC
RG7596	polatuzumab vedotin	r/r FL
RG7601	Venclexta + Rituxan	DLBCL
	Venclexta + azacitidine	1L MDS
	Venclexta + fulvestrant	2L HR+BC
RG6149	ST2 MAb	asthma
RG7159	obinutuzumab	lupus
RG7625	petesicatib	autoimmune diseases
RG7845	fenebrutinib	RA, lupus, CSU
CHU	nemolizumab#	pruritus in dialysis patients
NOV	TLR4 MAb	autoimmune diseases
RG1662	basmisanil	CIAS
RG6100	Tau MAb	Alzheimer's
RG7412	crenezumab	familial Alzheimer's healthy pts
RG7916	risdiplam §	SMA
RG7906	-	psychiatric disorders
RG7935	prasinezumab	Parkinson's
RG7716	faricimab	wAMD

New Molecular Entity (NME)
Additional Indication (AI)
Oncology
Immunology
Infectious Diseases
CardioMetabolism
Neuroscience
Ophthalmology
Other

RG-No - Roche/Genentech
CHU- Chugai managed
NOV- Novimmune managed
#out-licensed to Galderma and Maruho AD
§ Ph2 pivotal
TDB=T-cell dependent bispecific
*Individualized NeoAntigen Specific Immunotherapy, formerly PCV
T=Tecentriq; TCB=T-cell bispecific

Status as of January 31, 2019

Roche Group development pipeline

Phase III (11 NMEs + 35 AIs)

RG3502	Kadcyla	HER2+ eBC
	Kadcyla + Perjeta	HER2+ eBC
RG6264	Perjeta + Herceptin FDC SC	HER2+ BC
RG7388	idasanutlin + chemo	AML
RG7440	ipatasertib + abiraterone	1L CRPC
	ipatasertib + chemo	1L TNBC/HR+ BC
RG7421	Cotellic + Zelboraf+T	1L BRAFm melanoma
	Cotellic + T	1L BRAF WT melanoma
RG7596	polatuzumab vedotin	1L DLBCL
RG7446	Tecentriq	NSCLC adj
	Tecentriq	MIBC adj
	Tecentriq	NMIBC, high risk
	Tecentriq Dx+	1L sq + non-sq NSCLC
	Tecentriq	RCC adj
	T + chemo + Avastin	1L ovarian cancer
	T + pemetrexed	1L non-sq NSCLC
	T + nab-paclitaxel	1L sq NSCLC
	T ± chemo	SCCHN adj
	Tecentriq	HER2+ BC neoadj
	T + paclitaxel	1L TNBC
	T + capecitabine or carbo/gem	1L TNBC
	T + paclitaxel	TNBC adj
	T + nab-paclitaxel	TNBC neoadj
	T + Avastin	1L HCC
	T + Avastin	RCC
	T ± chemo	1L mUC
	T + enzalutamide	CRPC
RG7446/RG7853/ RG6268	Tecentriq or Alecensa or entrectinib	1L NSCLC Dx+
RG7601	Venclexta + Gazyva	1L CLL
	Venclexta + bortezomib	MM
	Venclexta	r/r MM t(11:14)
	Venclexta + HMA/LDA	1L AML
RG7853	Alecensa	NSCLC adj
RG3648	Xolair	nasal polyps
RG7413	etrolizumab	ulcerative colitis
	etrolizumab	Crohn's
RG6152	Xofluza	influenza, high risk
	Xofluza	influenza, hospitalized pts
	Xofluza	influenza, pediatric
RG1450	gantenerumab	Alzheimer's
RG6042	HTT ASO	Huntington's
RG6168	satralizumab	NMOSD
RG6206	anti-myostatin adnectin	DMD
RG7314	balovaptan	autism
RG3645	port delivery system with ranibizumab	wAMD
RG7716	faricimab	DME

Registration (3 NMEs + 8 AIs)

RG6013	Hemlibra[1]	hemophilia A w/o FVIII inh
	Hemlibra[1]	Q4W hemophilia A
RG6268	entrectinib	NSCLC ROS1+
	entrectinib	NTRK1 pantumor
RG7446	T + chemo + Avastin[1]	1L non-sq NSCLC
	T + nab-paclitaxel	1L non-sq NSCLC
	T + nab-paclitaxel	1L TNBC
	T + chemo	1L extensive stage SCLC
RG7596	polatuzumab vedotin	r/r DLBCL
RG105	MabThera[1]	pemphigus vulgaris
RG6152	Xofluza [1]	influenza

[1] Approved in US

New Molecular Entity (NME)
Additional Indication (AI)
Oncology
Immunology
Infectious Diseases

CardioMetabolism
Neuroscience
Ophthalmology
Other

RG-No Roche/Genentech

CHU Chugai managed

NOV Novimmune managed

#out-licensed to Galderma and Maruho AD

FDC=fixed-dose combination

T=Tecentriq; TCB=T-cell bispecific

TDB=T-cell dependent bispecific

Status as of January 31, 2019

NME submissions and their additional indications

Projects currently in phase II and III

2018		2019		2020		2021 and beyond					
		RG7916	risdiplam SMA			RG6058	tiragolumab + Tecentriq NSCLC	RG6042	HTT ASO Huntington's	RG3645	Port Delivery System with ranibizumab wAMD
		RG6168	satralizumab NMOSD	RG6206	anti-myostatin adnectin DMD	RG6180	iNeST oncology	RG1450	gantenerumab Alzheimer's	RG6149	ST2 MAb asthma
RG6152R	Xofluza (baloxavir marboxil) ✓ influenza (US)	RG6152	baloxavir marboxil influenza (EU)	RG6264	Perjeta + Herceptin FDC SC HER2+ BC	RG7388	idasanutlin polycythemia vera	RG1662	basmisanil CIAS	RG7413	etrolizumab ulcerative colitis
RG7596	polatuzumab vedotin✓ r/r DLBCL	RG6152	baloxavir marboxil influenza, high risk	RG7388	idasanutlin + chemo AML	RG7440	ipatasertib TNBC neoadj	RG6100	Tau MAb Alzheimer's	RG7413	etrolizumab Crohn's
RG6268	entrectinib (US)* ✓ NSCLC ROS1+	RG6268	entrectinib (EU) ✓ NSCLC ROS1+	RG7440	ipatasertib + abiraterone 1L CRPC	RG7596	polatuzumab vedotin 1L DLBCL	RG7314	balovaptan autism	RG7625	petesicatib autoimmune diseases
RG6268	entrectinib (US)* ✓ NTRK1 pantumor	RG6268	entrectinib (EU) ✓ NTRK1 pantumor	RG7440	ipatasertib +chemo 1L TNBC / HR+ BC	RG7596	polatuzumab vedotin r/r FL	RG7935	prasinezumab Parkinson's	RG7845	fenebrutinib autoimmune diseases
						RG6152	baloxavir marboxil influenza, pediatric				
						RG6152	baloxavir marboxil influenza, hospitalized pts	RG7716	faricimab wAMD		
								RG7716	faricimab DME		

*pending FDA acceptance of filing

✓ Indicates submission to health authorities has occurred
Unless stated otherwise submissions are planned to occur in US and EU

New Molecular Entity (NME)
Additional Indication (AI)
Oncology
Immunology
Infectious Diseases

CardioMetabolism
Neuroscience
Ophthalmology
Other

FDC =fixed-dose combination

Status as of January 31, 2019

AI submissions for existing products

Projects currently in phase II and III

2018		2019		2020		2021 and beyond			
RG105	**MabThera (EU) ✓** pemphigus vulgaris	RG3648	**Xolair** nasal polyps	RG3502	**Kadcyla + Perjeta** HER2+ eBC	RG7446/ RG7853/ RG6268	**Tecentriq or Alecensa or entrectinib** 1L NSCLC Dx+	RG7159	**obinutuzumab** lupus nephritis
RG1569	**Actemra auto injector (US)** RA ✓	RG3502	**Kadcyla** HER2+ eBC	RG7446	**Tecentriq + Avastin** RCC	RG7446	**Tecentriq SC** NSCLC	RG7421	**Cotellic + Tecentriq ± taxane** TNBC
RG1569	**Actemra (EU) ✓** CRS	RG7446	**Tecentriq + Avastin** 1L HCC	RG7446	**Tecentriq + paclitaxel** 1L TNBC	RG7446	**Tecentriq** NSCLC adj	RG7601	**Venclexta + HMA/LDAC** 1L AML
RG3648	**Xolair PFS (US)✓** Asthma & CIU	RG7421	**Cotellic + Tecentriq** 1L BRAF WT melanoma	RG7446	**Tecentriq** MIBC adj	RG7446	**Tecentriq** HER2+ BC neoadj	RG7601	**Venclexta** r/r MM t(11:14)
RG6013	**Hemlibra ✓** hemophilia A FVIII non-inh	RG7421	**Cotellic + Tecentriq + Zelboraf** 1L BRAFmut melanoma	RG7446	**Tecentriq ± chemo** 1L mUC	RG7446	**Tecentriq + paclitaxel** TNBC adj	RG7601	**Venclexta + Rituxan** DLBCL
RG6013	**Hemlibra ✓** hemophilia A, Q4W	RG7446	**Tecentriq** 1L non-sq + sq NSCLC (Dx+)	RG7446	**Tecentriq + enzalutamide** CRPC	RG7446	**Tecentriq** High risk NMIBC	RG7601	**Venclexta + azacitidine** 1L MDS
RG7601	**Venclexta + Rituxan (EU) ✓** r/r CLL	RG7446	**Tecentriq + nab-paclitaxel** TNBC neoadj	RG7446	**Tecentriq + chemo + Avastin** 1L ovarian cancer	RG7446	**Tecentriq** RCC adj	RG7601	**Venclexta+ fulvestrant** 2L HR+BC
RG7601	**Venclexta + HMA/LDAC (US) ✓** 1L AML	RG7446	**Tecentriq + nab-paclitaxel** 1L sq NSCLC			RG7446	**Tecentriq + chemo** SCCHN adj	RG7853	**Alecensa** NSCLC adj
RG7446	**Tecentriq + chemo + Avastin ✓** 1L non-sq NSCLC	RG7446	**Tecentriq + pemetrexed** 1L non-sq NSCLC			RG7446	**Tecentriq + capecitabine or carbo/gem** TNBC		
RG7446	**Tecentriq + nab-paclitaxel** 1L non-sq NSCLC✓	RG7601	**Venclexta + Gazyva** 1L CLL						
RG7446	**Tecentriq + chemo ✓** 1L extens. stage SCLC	RG7601	**Venclexta + bortezomib** MM						
RG7446	**Tecentriq + nab-paclitaxel** 1L TNBC ✓								

✓ Indicates submission to health authorities has occurred
Unless stated otherwise submissions are planned to occur in US and EU

New Molecular Entity (NME)
Additional Indication (AI)
Oncology
Immunology
Infectious Diseases
CardioMetabolism
Neuroscience
Ophthalmology
Other

Status as of January 31, 2019

Cancer immunotherapy pipeline overview

Phase I (10 NMEs + 26 AIs)

RG6026	CD20 TCB± chemo ± T	heme tumors
RG6123	-	solid tumors
RG6160	-	multiple myeloma
RG6180	iNeST (PCV) ± T	solid tumors
RG6194	HER2/CD3 TDB	BC
RG7421	Cotellic + Zelboraf + T	melanoma
	Cotellic + T	2L BRAF WT mM
	Cotellic + T	RCC, bladder, head & neck ca
RG7440	ipatasertib + Taxane + T	TNBC
RG7446	Tecentriq (T)	solid tumors
	Tecentriq (T)	NMIBC
	T-based Morpheus platform	solid tumors
	T + Avastin + Cotellic	2/3L CRC
	T ± Avastin ± chemo	HCC, GC, PaC
	T + Tarceva/Alecensa	NSCLC
	T + anti-CD20 combos	heme tumors
	T ± lenalidomide ± daratumumab	MM
	T + K/HP	HER2+ BC
	T + radium 223	mCRPC
	T + rucaparib	ovarian ca
RG7461	FAP IL2v FP combos	solid tumors
RG7601	Venclexta + Cotellic/idasanutlin	AML
	Venclexta + Cotellic + T	MM
RG7769	PD1-TIM3 biMAb	solid tumors
RG7802	cibisatamab ± T	solid tumors
RG7827	FAP-4-1BBL FP	solid tumors
RG7828	mosunetuzumab ± T	heme tumors
RG7876	selicrelumab + Avastin	solid tumors
AMGN**	Tecentriq + talimogene laherp	TNBC, CRC
BLRX**	Tecentriq + BL-8040	AML, solid tumors
CRVS**	Tecentriq + CPI-444	solid tumors
EXEL**	Tecentriq + cabozantinib	solid tumors
HALO**	Tecentriq + PEGPH20	CCC, GBC
INO**	Tecentriq + INO5401+INO9012	bladder ca
KITE**	Tecentriq + KTE-C19	r/r DLBCL

MORPHEUS Platform - Phase Ib/II (6 AIs)

RG7446	T-based Morpheus	pancreatic cancer
	T-based Morpheus	gastric cancer
	T-based Morpheus	HR+ BC
	T-based Morpheus	NSCLC
	T-based Morpheus	2L TNBC
	T-based Morpheus	CRC

Phase II (2 NMEs + 6 AIs)

RG6180	iNeST (PCV)+ pembrolizumab	malignant melanoma
RG6058	tiragolumab ± T	NSCLC
RG7421	Cotellic + Tecentriq ± taxane	TNBC
RG7446	Tecentriq SC	NSCLC
Gradalis**	Tecentriq + Vigil	ovarian ca
GTHX**	Tecentriq + trilaciclib	SCLC
IMDZ**	Tecentriq + NY-ESO-1	soft tissue sarcoma
SNDX**	Tecentriq + entinostat	TNBC

Phase III (21 AIs)

RG7421	Cotellic+Zelboraf+T	1L BRAFm melanoma
	Cotellic + T	1L BRAF WT melanoma
RG7446	Tecentriq	NSCLC adj
	Tecentriq	MIBC adj
	Tecentriq	high risk NMIBC
	Tecentriq Dx+	1L sq + non-sq SCLC
	Tecentriq	RCC adj
	T + chemo+ Avastin	1L ovarian cancer
	T + pemetrexed	1L non-sq NSCLC
	T + nab-paclitaxel	1L sq NSCLC
	T ± chemo	SCCHN adj
	Tecentriq	HER2-pos. BC neoadj
	T + nab-paclitaxel	1L TNBC
	T + capecitabine or carbo/gem	1L TNBC
	T + paclitaxel	TNBC adj
	T + nab-paclitaxel	TNBC neoadj
	T + Avastin	RCC
	T + Avastin	1L HCC
	T ± chemo	1L mUC
	T + enzalutamide	CRPC
RG7446/RG7853/ RG6268	Tecentriq or Alecensa or entrectinib	1L NSCLC Dx+

Registration (4 AIs)

RG7446	T + chemo + Avastin	1L non-sq NSCLC
	T + nab-paclitaxel	1L non-sq NSCLC
	T + chemo	1L extensive stage SCLC
	T + nab-paclitaxel	1L TNBC

** External collaborations: AMGN – Amgen oncolytic virus; BLRX - BioLine Rx CXCR4 antag; CRVS – Corvus ADORA2A antag; EXEL – Exelexis' TKI; Gradalis – EATC therapy; GTHX – G1 Therapeutics CDK4/6; HALO – Halozyme PEGPH20; IMDZ – Immune Design CMB305; INO - Inovio T cell activating immunotherapy (INO-5401), IL-12 activator (INO-9012); JNJ – Janssen CD38 MAb; KITE – Kite KTE-C19; SNDX – Syndax HDAC inh

New Molecular Entity (NME)
Additional Indication (AI)
Oncology

RG-No Roche/Genentech

T=Tecentriq; TCB=T-cell bispecific
TDB=T-cell dependent bispecific

Status as of January 31, 2019

Major granted approvals 2018

Approved

	US	EU	Japan-Chugai
	Lucentis 0.3 mg PFS DME/DR Mar 2018	**Ocrevus** PPMS & RMS, Jan 2018	**Hemlibra** hemophilia A FVIII inh (ped/adults), Mar 2018
RG435	**Avastin** Ovarian ca FL Jun 2018	**Perjeta + Herceptin** HER2+ BC adj, Jul 2018	**Gazyva** CD20+ FL, Jul 2018
RG6013	**Hemlibra** hemophilia A FVIII non-inh, Oct 2018	**Hemlibra** hemophilia A FVIII inh (ped/adults) Feb 2018	**Tecentriq** 2L NSCLC, Jan 2018
RG6013	**Hemlibra** Q4W hemophilia A Oct 2018	**Venclexta + Rituxan** r/r CLL, Nov 2018	**Perjeta + Herceptin** HER2+ BC adj, Oct. 2018
RG7446	**Tecentriq+chemo+Avastin** 1L non-sq NSCLC Dec. 2018	**Actemra auto injector** RA/GCA, Mar 2018	**Hemlibra** hemophilia A FVIII non-inh, Dec 2018
RG7601	**Venclexta + Rituxan** r/r CLL Jun 2018	**Actemra** CRS Sep 2018	**Hemlibra** Q4W hemophilia A, Dec 2018
RG7601	**Venclexta + HMA/LDAC** 1L AML Nov. 2018		**Tecentriq + other anti-tumor drugs** 1L NSCLC, Dec 2018
RG105	**Rituxan** pemphigus vulgaris, Jun 2018		
RG3648	**Xolair PFS** Asthma & CIU Sep 2018		
RG1569	**Actemra auto injector** RA, Nov 2018		
RG6152	**Xofluza** Influenza, Oct 2018		

- New Molecular Entity (NME)
- Additional Indication (AI)
- Oncology
- Immunology
- Infectious Diseases
- CardioMetabolism
- Neuroscience
- Ophthalmology
- Other

Status as of January 31, 2019

Major pending approvals 2019

Pending Approval

US		EU		Japan-Chugai	
RG7596	**polatzumab vedotin** r/r DLBCL Filed Dec 2018	RG7596	**polatzumab vedotin** r/r DLBCL Filed Dec 2018	RG1569	**Actemra** CRS, Filed May 2018
RG7446	**Tecentriq + nab-paclitaxel** 1L non sq NSCLC Filed Nov 2018	RG6013	**Hemlibra** hemophilia A FVIII non-inh, Filed Apr 2018	RG1569	**Actemra** Adult Onset Still's disease, Filed May 2018
RG7446	**Tecentriq + nab-paclitaxel** 1L TNBC Filed Sep 2018	RG6013	**Hemlibra** Q4W hemophilia A, Filed Apr 2018	RG7446	**Tecentriq + nab-paclitaxel** 1L TNBC Filed Dec 2018
RG7446	**Tecentriq + chemo** 1L extensive stage SCLC Filed Sep. 2018	RG7446	**Tecentriq + chemo + Avastin** 1L non-sq NSCLC Filed Feb 2018	RG7446	**Tecentriq + chemo** 1L extensive stage SCLC Filed Sep 2018
RG6268	**entrectinib** NSCLC ROS1+ Filed Dec 2018	RG7446	**Tecentriq + nab-paclitaxel** 1L non sq NSCLC Filed Oct 2018	RG6268	**entrectinib** NTRK+ solid tumors Filed Dec 2018
RG6268	**entrectinib** NTRK1 pan-tumor Filed Dec 2018	RG7446	**Tecentriq + nab-paclitaxel** 1L TNBC Filed Sep.2018		
		RG7446	**Tecentriq + chemo** 1L extensive stage SCLC Filed Sep. 2018		
		RG6268	**entrectinib** NSCLC ROS1+ Filed Jan 2019		
		RG6268	**entrectinib** NTRK1 pantumor Filed Jan 2019		
		RG105	**MabThera** pemphigus vulgaris, Filed Feb 2018		

New Molecular Entity (NME)
Additional Indication (AI)
Oncology
Immunology
Infectious Diseases
CardioMetabolism
Neuroscience
Ophthalmology
Other

Status as of January 31, 2019

Doing now what patients need next